Alimta Injection, Powder, Lyophilized, For Solution
Product Images NDC 0002-7640

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Alimta (NDC 0002-7640). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eli Lilly And Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Alimta 100mg 011 03

Packaging label for Alimta 100 mg injection, powder lyophilized for solution, pemetrexed for injection, single-dose vial. The label indicates reconstitution instructions, storage conditions, and warnings. Marketed by Lilly USA, LLC with prominently displayed brand and generic names and dosage strength.*

FDA Label Image

Alimta 500mg 010 03

Packaging label for Alimta 500 mg injection, lyophilized powder for solution, containing pemetrexed disodium. The label indicates a single-dose vial marketed by Eli Lilly and Company, with storage and reconstitution instructions, dosage information, and a caution that it is a cytotoxic agent. The label includes branding, dosage form, route of administration, and regulatory details.*

FDA Label Image

Structural Formula (Alimta F01 V01)

Chemical structure diagram of Pemetrexed disodium, the active ingredient in Alimta injection. The structure shows the molecular framework, including functional groups and sodium ions, with seven water molecules indicated as hydration.*

FDA Label Image

Figure 1 (Alimta F05 V04)

A survival curve line graph comparing survival probability over time in months between two patient groups: those treated with Alimta plus Cisplatin (AC) and those treated with Gemcitabine plus Cisplatin (GC). The graph includes a table of patients at risk at different time points for each group below the x-axis.*

FDA Label Image

Figure 2 (Alimta F08 V3)

A survival probability curve comparing two treatment regimens over 30 months. The solid line represents Alimta plus Cisplatin (AC), and the dotted line represents Gemcitabine plus Cisplatin (GC). Below the graph, a table shows the number of patients at risk at various time points for each group.*

FDA Label Image

Figure 4 (Alimta F12 V3)

A Kaplan-Meier survival curve chart comparing the survival probability over time (in months) between patients treated with Alimta (solid line) and a placebo (dotted line). The x-axis represents survival time in months, and the y-axis shows the survival probability. A table below the x-axis lists the number of patients at risk at different time points for both Alimta and placebo groups.*

FDA Label Image

Figure 5 (Alimta F13 V2)

A survival probability graph comparing ALIMTA to placebo over survival time in months. The y-axis represents survival probability from 0 to 1, and the x-axis shows survival time up to 42 months. The solid line depicts ALIMTA, and the dotted line depicts placebo. Below the x-axis is a table indicating the number of patients at risk at various time points for both ALIMTA and placebo groups.*

FDA Label Image

Figure 7 (Alimta F14 V2)

A survival probability curve chart comparing ALIMTA (pemetrexed disodium) to placebo over time in months. The y-axis represents survival probability from 0.0 to 1.0, and the x-axis shows survival time in months from 0 to 36. Two curves are shown: a solid line for ALIMTA and a dotted line for placebo. Numerical data on patients at risk for both ALIMTA and placebo groups are listed below the x-axis.*

FDA Label Image

Figure 3 (Alimta F15 V01)

This chart depicts a Kaplan-Meier survival curve showing survival probability over time in months for two treatment groups: Alimta plus Cisplatin (AC) and Gemcitabine plus Cisplatin (GC). The graph includes a table below indicating the number of patients at risk at selected time points for each group.*

FDA Label Image

Figure 6 (Alimta F16 V1)

A Kaplan-Meier survival curve comparing survival probability over time (months) between ALIMTA and placebo groups. The solid line represents ALIMTA, and the dotted line represents placebo. Below the graph, the number of patients at risk is listed for each group at various time points.*

FDA Label Image

Figure 8 (Alimta F17 V1)

A Kaplan-Meier survival curve chart showing survival probability over time in months for two groups: ALIMTA + Cisplatin (solid line) and Cisplatin alone (dotted line). The x-axis represents survival time in months, and the y-axis represents survival probability. Below the graph are numbers of patients at risk for each time point in both groups.*

FDA Label Image

Alimta F18 V1

A Kaplan-Meier survival curve showing overall survival percentage over time in months for two treatment arms involving Alimta. The black line represents the A+P+C arm (ALIMTA with pembrolizumab and platinum chemotherapy), and the gray dashed line represents the A+C arm (ALIMTA with platinum chemotherapy and placebo). A number-at-risk table is included below the plot, showing sample sizes at various time points up to 21 months.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.